These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 28537216)

  • 1. Regulation of drug-metabolizing enzymes in infectious and inflammatory disease: implications for biologics-small molecule drug interactions.
    Mallick P; Taneja G; Moorthy B; Ghose R
    Expert Opin Drug Metab Toxicol; 2017 Jun; 13(6):605-616. PubMed ID: 28537216
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regulation of drug-metabolizing enzymes by local and systemic liver injuries.
    Guo Y; Hu B; Xie Y; Billiar TR; Sperry JL; Huang M; Xie W
    Expert Opin Drug Metab Toxicol; 2016; 12(3):245-51. PubMed ID: 26751558
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of renal diseases on the regulation and expression of renal and hepatic drug-metabolizing enzymes: a review.
    Korashy HM; Elbekai RH; El-Kadi AO
    Xenobiotica; 2004 Jan; 34(1):1-29. PubMed ID: 14742134
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug disposition in pathophysiological conditions.
    Gandhi A; Moorthy B; Ghose R
    Curr Drug Metab; 2012 Nov; 13(9):1327-44. PubMed ID: 22746301
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Important role of proinflammatory cytokines/other endogenous substances in drug-induced hepatotoxicity: depression of drug metabolism during infections/inflammation states, and genetic polymorphisms of drug-metabolizing enzymes/cytokines may markedly contribute to this pathology.
    Prandota J
    Am J Ther; 2005; 12(3):254-61. PubMed ID: 15891270
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inflammation-induced phenoconversion of polymorphic drug metabolizing enzymes: hypothesis with implications for personalized medicine.
    Shah RR; Smith RL
    Drug Metab Dispos; 2015 Mar; 43(3):400-10. PubMed ID: 25519488
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulation of cytochromes P450 during inflammation and infection.
    Morgan ET
    Drug Metab Rev; 1997 Nov; 29(4):1129-88. PubMed ID: 9421688
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current status of novel biologics and small molecule drugs in the individualized treatment of inflammatory bowel disease.
    Xu YH; Zhu WM; Guo Z
    World J Gastroenterol; 2022 Dec; 28(48):6888-6899. PubMed ID: 36632311
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of liver diseases on drug-metabolizing enzymes: implications for drug fate alterations and nano-therapeutic openings.
    Lu L; Shi J; Li Q; Peng X; Dong L; Li Y; Dai P; Wang Y; Guo E; Zhou F; Liu Z
    Curr Med Chem; 2014; 21(22):2522-41. PubMed ID: 24358976
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biologics and Cardiovascular Disease.
    Van Taunay JS; Albelda MT; Frias JC; Lipinski MJ
    J Cardiovasc Pharmacol; 2018 Aug; 72(2):77-85. PubMed ID: 29738370
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug metabolizing enzymes-associated chemo resistance and strategies to overcome it.
    Verma H; Singh Bahia M; Choudhary S; Kumar Singh P; Silakari O
    Drug Metab Rev; 2019 May; 51(2):196-223. PubMed ID: 31203662
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of microRNAs in the regulation of drug metabolism and disposition.
    Yu AM
    Expert Opin Drug Metab Toxicol; 2009 Dec; 5(12):1513-28. PubMed ID: 19785514
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potential role of drug metabolizing enzymes in chemotherapy-induced gastrointestinal toxicity and hepatotoxicity.
    Tao G; Huang J; Moorthy B; Wang C; Hu M; Gao S; Ghose R
    Expert Opin Drug Metab Toxicol; 2020 Nov; 16(11):1109-1124. PubMed ID: 32841068
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of pharmacogenetics of drug-metabolizing enzymes in treating osteosarcoma.
    Hattinger CM; Serra M
    Expert Opin Drug Metab Toxicol; 2015; 11(9):1449-63. PubMed ID: 26095223
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The development of biological therapies for neurological diseases: moving on from previous failures.
    Qosa H; Volpe DA
    Expert Opin Drug Discov; 2018 Apr; 13(4):283-293. PubMed ID: 29394876
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biologic response modifiers: Indications, implications, and insights.
    Davis BP; Ballas ZK
    J Allergy Clin Immunol; 2017 May; 139(5):1445-1456. PubMed ID: 28263774
    [TBL] [Abstract][Full Text] [Related]  

  • 17. INTEDE: interactome of drug-metabolizing enzymes.
    Yin J; Li F; Zhou Y; Mou M; Lu Y; Chen K; Xue J; Luo Y; Fu J; He X; Gao J; Zeng S; Yu L; Zhu F
    Nucleic Acids Res; 2021 Jan; 49(D1):D1233-D1243. PubMed ID: 33045737
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optical substrates for drug-metabolizing enzymes: Recent advances and future perspectives.
    Jin Q; Wu J; Wu Y; Li H; Finel M; Wang D; Ge G
    Acta Pharm Sin B; 2022 Mar; 12(3):1068-1099. PubMed ID: 35530147
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological interactions of monoclonal antibodies.
    Serra López-Matencio JM; Morell Baladrón A; Castañeda S
    Med Clin (Barc); 2018 Aug; 151(4):148-155. PubMed ID: 29269128
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regulation of gene expression of hepatic drug metabolizing enzymes and transporters by the Toll-like receptor 2 ligand, lipoteichoic acid.
    Ghose R; Guo T; Haque N
    Arch Biochem Biophys; 2009 Jan; 481(1):123-30. PubMed ID: 18940178
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.